Nesiritide for Ventilated Congestive Heart Failure

Congestive Heart Failure Clinical Trial

— HENCHF  

Official title:

Hemodynamic Effects of Nesiritide on Congestive Heart Failure Patients Receiving Mechanical Ventilation: A Prospective Observational Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04455477
• Other study ID #: B2020-056R
• Status: Recruiting
• Start date: May 14, 2020
• Est. completion date: December 31, 2021

Study information

• Verified date: June 2020
• Source: Shanghai Zhongshan Hospital
• Contact: Zhe Luo, MD
• Phone: +8613916127028
• Email: luo.zhe[@]zs-hospital.sh.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The congestive heart failure is a common disease among patients who receive cardiac surgery and may lead to prolonged ventilation support. Nesiritide was a potential therapy for congestive heart failure. This study aimed to compare the Nesiritide induced hemodynamical status changes among congestive heart failure patients with invasive ventilation support.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2021
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age=18 years;

• Congestive Heart Failure;

• With mechanical ventilation;

• With hemodynamic monitoring devices;

• The physicians made the decision of using Nesiritide.

Exclusion Criteria:

• Unstable hemodynamic status;

• Severe renal dysfunction.

Related Conditions & MeSH terms

• Cardiac Function
• Congestive Heart Failure
• Heart Failure
• Mechanical Ventilation
• Using Nesiritide
• Venous Return

Intervention

Drug:
• Nesiritide
The attending physicans decide whether to use Nesiritide for congestive heart failure patients. Only patients who will use Nesiritide are enrolled.

Locations

Country	Name	City	State
China	Zhongshan Hospital	Xuhui	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Zhongshan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes of cardiac output	Changes of cardiac output measured by hemodynamical monitoring tools	Before and 30-min after using a standard dose of Nesiritide
Primary	Changes of systemic filling pressure	Changes of the intercept of regression line of paired VR-RAP points at different PEEP levels.	Before and 30-min after using a standard dose of Nesiritide
Secondary	Changes of cardiac function curve	Using body position changes (±15°) to simulate the change of preload, and therefore depicte the Starling curve	Before and 30-min after using a standard dose of Nesiritide
Secondary	Changes of venous return curve	Changes of venous return curve depicted by different PEEP setting	Before and 30-min after using a standard dose of Nesiritide